Intraoperative Electroencephalographic Biomarkers of Postoperative Pain

March 12, 2024 updated by: University of Chile

Determination of the Association of Intraoperative Nociception Electroencephalographic Biomarkers and Postoperative Pain

The goal of this study is to explore whether specific intraoperative EEG signals (brain waves or neuronal electrical activity) are associated with the severity of acute postoperative pain.

Study Overview

Status

Not yet recruiting

Detailed Description

This is a prospective minimal-risk observational study to collect and analyze EEG data during intraepidermal electrical stimulation in patients receiving general anesthesia (GA) for abdominal surgery. To collect nociception-related EEG signal during GA the investigators designed a standardized Intraepidermal Electrical Stimulation (IES) Protocol. The intensity of the electrical stimulus will be calibrated to each participant perception pre-surgery, with 3 different intensities: sensitivity threshold, mild-pain threshold, and moderate-pain threshold. The IES will be administered several times throughout the surgical procedure: a) At baseline, prior to induction of GA, b) Three minutes after loss of consciousness, c) Five minutes after fentanyl administration and orotracheal intubation, d) Five minutes after first incision and every 20 minutes until the end of the surgery, and f) After surgery ends and before extubation. To standardize the anesthesia management as much as possible, all patients will be attended by a reduced number of anesthesiologists. The hypnosis will be achieved with propofol, while analgesia will be mainly achieved with either fentanyl or remifentanil. EEG will be recorded with a 32-channel high standard equipment. Once the patient arrives to the Post-Anesthesia Care Unit (PACU), the investigators will record the pain reported by the patient using the Numeric Pain Rating Scale every 15 minutes during the first hour, and every 30 minutes until patient is discharged from the PACU. Also, the investigators will both, record opioid administration through the surgery and estimate their effect-site concentration with pharmacokinetic/pharmacodynamic models. Besides, the investigators will measure opioid plasmatic concentrations.

Study Type

Observational

Enrollment (Estimated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Santiago, Chile
        • Centro de Investigacion Clinica Avanzada
    • RM
      • Santiago, RM, Chile, 7563215
        • Hospital Clinico de la Universidad de Chile
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Adult patients schedule for elective abdominal surgery under general anesthesia.

Description

Inclusion Criteria:

  • American Society of Anesthesiologist Performance Status I or II
  • Scheduled for elective laparoscopic abdominal surgery under General Anesthesia

Exclusion Criteria:

  • Body Mass Index > 35 kg/m2
  • Past history or suspected difficult airway
  • Craniofacial malformations
  • Use of regional anesthesia technique during or after the surgery
  • Severe arrhythmia or use of a pacemaker device
  • Severe neuropsychiatric illness (Mayor depression, bipolar disorder, schizophrenia)
  • Regular use of psychoactive drugs
  • Any injury in the right hand
  • Past history of peripheral neuropathy
  • Diabetes Mellitus
  • Known lesion in the spinothalamic tract.
  • Analgesics used in the past 72 hours
  • Known allergy to propofol
  • Previous diagnosis of a condition associated with chronic pain (such as fibromyalgia, rheumatoid arthritis, osteoarthritis, migraine)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximum Pain in PACU
Time Frame: From PACU Admission to PACU Discharged, an average of 2 hours
Pain is evaluated several times during PACU stay using the Numeric Rating Scale (from 0 to 10). Discrete Numerical Variable
From PACU Admission to PACU Discharged, an average of 2 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Opioid Consumption in PACU
Time Frame: From PACU Admission to PACU Discharged, an average of 72 hours
Total opioid administered during PACU stay in Morphine Milligram Equivalent (MME). Continuous Numerical Variable.
From PACU Admission to PACU Discharged, an average of 72 hours
Maximum Pain at 24h
Time Frame: From PACU discharged to 24 hours after PACU discharged
Pain is evaluated several times during hospital stay using the Numeric Rating Scale (from 0 to 10). This outcome corresponds to the maximum pain reported by the patient during the time frame. Discrete Numerical Variable.
From PACU discharged to 24 hours after PACU discharged
Presence of surgical related pain at day 7
Time Frame: 7 days after the surgery (+- 1 day)
Pain of any intensity (Numeric Rating Scale >1) reported by the patient 7 days after the surgery
7 days after the surgery (+- 1 day)
Presence of surgical related pain at day 30
Time Frame: 30 days after surgery (+- 3 day)
Pain of any intensity (Numeric Rating Scale >1) reported by the patient 30 days after the surgery
30 days after surgery (+- 3 day)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Rodrigo Gutierrez, MD, PhD, University of Chile

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2024

Primary Completion (Estimated)

March 1, 2026

Study Completion (Estimated)

June 1, 2026

Study Registration Dates

First Submitted

March 6, 2024

First Submitted That Met QC Criteria

March 12, 2024

First Posted (Actual)

March 15, 2024

Study Record Updates

Last Update Posted (Actual)

March 15, 2024

Last Update Submitted That Met QC Criteria

March 12, 2024

Last Verified

December 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Nociceptive Pain

3
Subscribe